Masanori Kaneuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masanori Kaneuchi has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Satoru Nagase
Department of Obstetrics and Gynecology, Yamagata University, Yamagata, Japan
9 shared publications - Mikio Mikami
Department of Medical Science, Shonan University of Medical Science, Yokohama, Japan
8 shared publications - Tsutomu Tabata
Department of Obstetrics and Gynecology Tokyo Women's Medical University Tokyo Japan
8 shared publications - Yoichi Kobayashi
Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Tokyo, Japan
8 shared publications - Wataru Yamagami
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
6 shared publications - Hideki Tokunaga
Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
5 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36  (5)
Quality indicators for endometrial cancer care in Japan
Kakuwa T, et al. J Gynecol Oncol. 2025 Mar;36:e77. https://doi.org/10.3802/jgo.2025.36.e77
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36  (5)
Open AccessQuality indicators for endometrial cancer care in Japan
Kakuwa T, et al. J Gynecol Oncol. 2025 Mar;36:e77. https://doi.org/10.3802/jgo.2025.36.e77
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36  (5)
Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan
Kakuwa T, et al. J Gynecol Oncol. 2025 Mar;36:e78. https://doi.org/10.3802/jgo.2025.36.e78
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36  (5)
Open AccessRevision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan
Kakuwa T, et al. J Gynecol Oncol. 2025 Mar;36:e78. https://doi.org/10.3802/jgo.2025.36.e78
- Top Cited PapersOpen Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35  (1) , e15
Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment
Seino M, et al. J Gynecol Oncol. 2023 Nov;35(1):e15. https://doi.org/10.3802/jgo.2024.35.e15
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35  (1) , e15
Top Cited PapersOpen AccessJapan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment
Seino M, et al. J Gynecol Oncol. 2023 Nov;35(1):e15. https://doi.org/10.3802/jgo.2024.35.e15
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34  (1)
Impact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study
Seino M, et al. J Gynecol Oncol. 2022 Sep;34(1):e4. https://doi.org/10.3802/jgo.2023.34.e4
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34  (1)
Open AccessImpact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study
Seino M, et al. J Gynecol Oncol. 2022 Sep;34(1):e4. https://doi.org/10.3802/jgo.2023.34.e4
- 25 May 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27  (8) , 1247-1255
Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis
Sentinel node navigation surgery (SNNS) is used in clinical practice for the treatment of cervical cancer. This study aimed to elucidate the appropriate sentinel lymph node (SLN) mapping method and assess the safety and benefits of SNNS. We searched the PubMed, Ichushi, and Cochrane Library databases for randomized controlled trials (RCT) and studies on SLN in cervical cancer from January 2012 to December 2020. Two authors independently assessed study quality and extracted data. We quantitatively analyzed the detection rate, sensitivity/specificity, and complications and reviewed information, including the survival data of SLN biopsy (SLNB) without pelvic lymphadenectomy (PLND). The detection rate of SLN mapping in the unilateral pelvis was median 95.7% and 100% and in the bilateral pelvis was median 80.4% and 90% for technetium-99 m (Tc) with/without blue dye (Tc w/wo BD) and indocyanine green (ICG) alone, respectively. The sensitivity and specificity of each tracer were high; the area under the curve of each tracer was 0.988 (Tc w/wo BD), 0.931 (BD w/wo Tc), 0.966 (ICG), and 0.977 (carbon nanoparticle). Morbidities including lymphedema, neurological symptoms and blood loss were associated with PLND. One RCT and five studies all showed SNNS without systematic PLND does not impair recurrence or survival in early-stage cervical cancer with a tumor size ≤ 2–4 cm. Both Tc w/wo BD and ICG are appropriate SLN tracers. SNNS can reduce the morbidities associated with PLND without affecting disease progression in early-stage cervical cancer.
- 25 May 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27  (8) , 1247-1255
Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis
Sentinel node navigation surgery (SNNS) is used in clinical practice for the treatment of cervical cancer. This study aimed to elucidate the appropriate sentinel lymph node (SLN) mapping method and assess the safety and benefits of SNNS. We searched the PubMed, Ichushi, and Cochrane Library databases for randomized controlled trials (RCT) and studies on SLN in cervical cancer from January 2012 to December 2020. Two authors independently assessed study quality and extracted data. We quantitatively analyzed the detection rate, sensitivity/specificity, and complications and reviewed information, including the survival data of SLN biopsy (SLNB) without pelvic lymphadenectomy (PLND). The detection rate of SLN mapping in the unilateral pelvis was median 95.7% and 100% and in the bilateral pelvis was median 80.4% and 90% for technetium-99 m (Tc) with/without blue dye (Tc w/wo BD) and indocyanine green (ICG) alone, respectively. The sensitivity and specificity of each tracer were high; the area under the curve of each tracer was 0.988 (Tc w/wo BD), 0.931 (BD w/wo Tc), 0.966 (ICG), and 0.977 (carbon nanoparticle). Morbidities including lymphedema, neurological symptoms and blood loss were associated with PLND. One RCT and five studies all showed SNNS without systematic PLND does not impair recurrence or survival in early-stage cervical cancer with a tumor size ≤ 2–4 cm. Both Tc w/wo BD and ICG are appropriate SLN tracers. SNNS can reduce the morbidities associated with PLND without affecting disease progression in early-stage cervical cancer.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33  (3)
Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system
Machida H, et al. J Gynecol Oncol. 2022 Feb;33:e26. https://doi.org/10.3802/jgo.2022.33.e26
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33  (3)
Open AccessSignificance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system
Machida H, et al. J Gynecol Oncol. 2022 Feb;33:e26. https://doi.org/10.3802/jgo.2022.33.e26
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33  (2) , e14
Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study
Kondo E, et al. J Gynecol Oncol. 2021 Dec;33:e14. https://doi.org/10.3802/jgo.2022.33.e14
- 1 January 2022
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33  (2) , e14
Open AccessComparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study
Kondo E, et al. J Gynecol Oncol. 2021 Dec;33:e14. https://doi.org/10.3802/jgo.2022.33.e14
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32  (2) , e49
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
Tokunaga H, et al. J Gynecol Oncol. 2021 Feb;32(2):e49. https://doi.org/10.3802/jgo.2021.32.e49
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32  (2) , e49
Open AccessThe 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
Tokunaga H, et al. J Gynecol Oncol. 2021 Feb;32(2):e49. https://doi.org/10.3802/jgo.2021.32.e49
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31  (3) , e49
Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer
Sakuragi N, et al. J Gynecol Oncol. 2019 Jun;31:e49. https://doi.org/10.3802/jgo.2020.31.e49
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31  (3) , e49
Open AccessNerve-sparing radical hysterectomy in the precision surgery for cervical cancer
Sakuragi N, et al. J Gynecol Oncol. 2019 Jun;31:e49. https://doi.org/10.3802/jgo.2020.31.e49
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31  (1) , e18
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms
The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a "Recommendations for tomorrow".
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31  (1) , e18
Open AccessJapan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms
The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a "Recommendations for tomorrow".